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TRM 24% 10% 0.06
Relapse 43% 36% 0.5
OS 39% 62% 0.02
DFS 34% 54% 0.04
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relapsed following an allogeneic HCT for a myeloid malig-
nancy at Mayo Clinic in Arizona was performed. The BM
sample closest in time prior to relapse was identiﬁed and the
morphologic, ﬂow cytometric, karyotypic, FISH, PCR and
chimerism results were reviewed.
Results: Out of 187 patients with a myeloid malignancy, 40
(31 AML, 4 MPN blast crisis, 4 MDS, 1 CML) relapsed at
a median of 113 days (range 22-820 days) after HCT. Thirty
percent of the relapses occurred after a myeloablative HCT.
Donor type was equally distributed between matched
related and mismatched/ matched unrelated donors. A
cytogenetic and molecular marker with the diagnosis was
identiﬁable in 22/40 and 6/40 patients respectively. 18/40
patients had residual disease present at HCT. 13/40 patients
showed an early relapse within the ﬁrst 90 days. In the
remaining patients, time between the last BM and relapse
ranged from 38-184 days (median 69). Abnormal results
were found only in 9/27 patients in the preceding BM and
included abnormal cytogenetic clone identical to diagnosis in
2 patients; abnormal RT-PCR for BCR/ABL in 1, cytogenetic
abnormality in donor cell line in 3, and decreased chime-
risms in unsorted marrow cells in 3 patients.
Conclusions: A 3-month monitoring schedule of BM evalu-
ation using the currently available tools had low sensitivity
to predict relapse. Findings that may justify intervention
were rare (less than 10% of patients), and were restricted to
abnormal cytogenetic and abnormal RT-PCR results. The
clinical signiﬁcance of cytogenetic abnormalities observed in
donor cells is not clear. Our ﬁndings emphasize that until the
optimal surveillance technique and schedule can be deﬁned
and standardized, more frequent use of pre-emptive therapy
in patients at high risk of relapse may be of beneﬁt.228
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Reduced intensity conditioning (RIC) with ﬂudarabine
(Flu) and sub-myeloablative doses of busulfan (Bu) (<8 mg/
kg) has low transplant related mortality (TRM) compared to
myeloablative (MA) conditioning, and is increasingly utilized
in older and medically inﬁrm pts. Flu with MA Bu (>8mg/kg)
using pharmacokinetic (PK) dosing also has low TRM, but
randomized comparisons to RIC are lacking. Therefore, we
compared RIC and MA FluBu dosing on TRM, relapse and
survival in remission AML. We reviewed AML pts receiving
allogeneic hematopoietic stem cell transplant (HSCT) in
remission (CR1/CR2) at the University of Michigan from 2003
e 2011. RIC (FluBu2) was ﬂu 40mg/m2 x 4 days with IV Bu 3.2
mg/kg x 2 days. FluBu2 included TLI/TBI (200cGy) in 39% of
cases, and ATG in one case. MA (FluBu4) was ﬂu 40mg/m2 x 4
days with IV Bu 3.2 mg/kg x 4 days with PK adjustment to
a target Css of 600-900 mcg/L (Seattle PK lab). FluBu4 had no
TBI/TLI/ATG. Pt <18 yrs, cords, prior HSCT and active AMLwere excluded. Cumulative incidence of GVHD, TRM and
relapse were calculated with competing risks. A total of 122
pts (FluBu2¼71; FluBu4¼51) were identiﬁed. Most primary
GVHD prophy was tacro + MMF for FluBu2 (89%), and tacro +
MTX for FluBu4 (86%). FluBu2 pts were older (60 vs. 51; P <
.01), but donor type, HLA match, and disease risk (cytoge-
netics / FLT3 ITD) were not signiﬁcantly different. There was
a trend towards higher ( 3) comorbidity index scores in
FluBu2 (42% vs. 25%; P ¼ .09). All FluBu4 pts engrafted; two
graft failures occurred (3%) in FluBu2. TRM did not differ at
day 100 (FluBu2¼0% vs. FluBu4¼2%; P ¼ .3) or 1 yr
(FluBu2¼17% vs. FluBu4¼10%; P ¼ .3), but by 3 yrs there was
a trend towards greater TRM in FluBu2 (FluBu2¼24% vs.
FluBu4¼10%; P ¼ .06). After adjusting for donor type, HLA
match, age, and HSCT-CI the trend for greater TRM in FluBu2
remained (HR: 3.5, P ¼ .04, 95% CI: 1.1 e11.0). Pts with HSCT-
CI  3, had similar TRM with FluBu2 (HR: 1.5, P ¼ .6, 95% CI:
0.4 e 5.7). Acute GVHD grade II-IV was not signiﬁcantly
different between FluBu2 and FluBu4 (38% vs. 24%; P ¼ .09).
Chronic GVHD caused late deaths in 10% of FluBu2, and in 4%
of FluBu4. There was no signiﬁcant difference in relapse at 3
yrs (FluBu2¼43% vs FluBu4¼36%, P ¼ .5). Overall survival
(OS) favored FluBu4 compared to FluBu2 (OS: 62% vs. 39%; P
¼ .02). This difference in OS was greater in intermediate risk
AML (74% vs 50%; P¼ .07), compared to high risk AML (40% vs
28%, P ¼ .5). FluBu4 pts had a non-signiﬁcant OS advantage
after multivariate analysis including donor type, HLA match,
and disease risk (HR: 1.75, P ¼ .06, 95% CI: 1.0 e 3.1). In
summary, MA conditioning with FluBu4 did not increase
TRM compared to RIC with FluBu2. The potential survival
beneﬁt of FluBu4 in remission AML requires prospective
validation.229
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Background: IFD is a major cause of morbidity andmortality
after intensive chemotherapy and HSCT in patients with
hematologic malignancies. MBL is a member of the C-type
lectin superfamily of microbe pattern recognition molecules.
Several studies have suggested an association of MBL levels
below 1,000 ng/ml with a variety of infectious complications
in cancer therapy, but there are conﬂicting data. The aim of
this study was to investigate the association between low
MBL levels and the development of IFD in patients with
hematologic malignancies undergoing chemotherapy or
HSCT.
